SciSparc Announces Publication of Japanese Patent Application

Core Viewpoint - SciSparc Ltd. has announced the publication of a Japanese divisional patent for a novel pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA), which may provide enhanced pain and fever relief with lower doses and fewer side effects compared to traditional paracetamol use [1][2]. Group 1: Patent and Innovation - The newly published patent introduces a combination of paracetamol and PEA that could lead to safer and more effective treatment options for millions globally [2]. - The combination aims to reduce the required dosage of paracetamol, thereby minimizing risks such as liver damage while improving outcomes for various types of pain and fever [3]. Group 2: Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid pharmaceuticals [4]. - The company is currently engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [4].